Literature DB >> 33718202

Hyperglycemia and Chemoresistance in Breast Cancer: From Cellular Mechanisms to Treatment Response.

Jie Qiu1, Qinghui Zheng2, Xuli Meng2.   

Abstract

Female breast cancer is a complex, multifactorial disease. Studies have shown that hyperglycemia is one of the most important contributing factors to increasing the risk of breast cancer that also has a major impact on the efficacy of chemotherapy. At the cellular level, hyperglycemia can promote the proliferation, invasion, and migration of breast cancer cells and can also induce anti-apoptotic responses to enhance the chemoresistance of tumors via abnormal glucose metabolism. In this article, we focus on the latest progress in defining the mechanisms of chemotherapy resistance in hyperglycemic patients including the abnormal behaviors of cancer cells in the hyperglycemic microenvironment and the impact of abnormal glucose metabolism on key signaling pathways. To better understand the advantages and challenges of breast cancer treatments, we explore the causes of drug resistance in hyperglycemic patients that may help to better inform the development of effective treatments.
Copyright © 2021 Qiu, Zheng and Meng.

Entities:  

Keywords:  breast cancer; chemoresistance; chemotherapy resistance; glucose metabolism; hyperglycemia

Year:  2021        PMID: 33718202      PMCID: PMC7947364          DOI: 10.3389/fonc.2021.628359

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  100 in total

1.  The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

Authors:  Mengjia He; Qianni Jin; Cong Chen; Yifeng Liu; Xiangsen Ye; Yulin Jiang; Feihu Ji; Husun Qian; Delu Gan; Shujun Yue; Wei Zhu; Tingmei Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

2.  The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.

Authors:  Isabel Pimentel; Bingshu E Chen; Ana Elisa Lohmann; Marguerite Ennis; Jennifer Ligibel; Lois Shepherd; Dawn L Hershman; Timothy Whelan; Vuk Stambolic; Ingrid Mayer; Timothy Hobday; Julie Lemieux; Alastair Thompson; Priya Rastogi; Karen Gelmon; Daniel Rea; Manuela Rabaglio; Susan Ellard; Mihaela Mates; Philippe Bedard; Lacey Pitre; Theodore Vandenberg; Ryan J O Dowling; Wendy Parulekar; Pamela J Goodwin
Journal:  J Natl Cancer Inst       Date:  2021-02-01       Impact factor: 13.506

3.  Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.

Authors:  Ran Wei; Limin Mao; Ping Xu; Xinghai Zheng; Robert M Hackman; Gerardo G Mackenzie; Yuefei Wang
Journal:  Food Funct       Date:  2018-11-14       Impact factor: 5.396

Review 4.  Everolimus is a new anti-cancer molecule: Metabolic side effects as lipid disorders and hyperglycemia.

Authors:  L Morviducci; F Rota; L Rizza; P Di Giacinto; S Ramponi; M R Nardone; C Tubili; A Lenzi; P Zuppi; R Baldelli
Journal:  Diabetes Res Clin Pract       Date:  2018-04-21       Impact factor: 5.602

5.  The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.

Authors:  Alexander M Scherbakov; Danila V Sorokin; Victor V Tatarskiy; Nikolay S Prokhorov; Svetlana E Semina; Lev M Berstein; Mikhail A Krasil'nikov
Journal:  IUBMB Life       Date:  2016-02-19       Impact factor: 3.885

6.  FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.

Authors:  Min Xu; Shuzheng Chen; Weibin Yang; Xue Cheng; Yani Ye; Jianting Mao; Xulu Wu; Li Huang; Jiansong Ji
Journal:  Cell Physiol Biochem       Date:  2018-05-10

Review 7.  Type 2 diabetes, insulin treatment and prognosis of breast cancer.

Authors:  Lan Mu; Nannan Zhu; Jiao Zhang; Fang Xing; Daiqing Li; Xin Wang
Journal:  Diabetes Metab Res Rev       Date:  2016-06-20       Impact factor: 4.876

8.  Stromal Infiltration of Tumor-Associated Macrophages Conferring Poor Prognosis of Patients with Basal-Like Breast Carcinoma.

Authors:  Mu Yang; Zhenhua Li; Meijing Ren; Shuai Li; Lanjing Zhang; Xinmin Zhang; Fangfang Liu
Journal:  J Cancer       Date:  2018-06-06       Impact factor: 4.207

9.  UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression.

Authors:  James M Arnold; Franklin Gu; Chandrashekar R Ambati; Uttam Rasaily; Esmeralda Ramirez-Pena; Robiya Joseph; Mohan Manikkam; Rebeca San Martin; Christy Charles; Yinghong Pan; Sujash S Chatterjee; Petra Den Hollander; Weijie Zhang; Chandandeep Nagi; Andrew G Sikora; David Rowley; Nagireddy Putluri; Xiang H-F Zhang; Balasubramanyam Karanam; Sendurai A Mani; Arun Sreekumar
Journal:  Oncogene       Date:  2019-07-15       Impact factor: 9.867

10.  Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.

Authors:  Kai Hung Tiong; Boon Shing Tan; Heng Lungh Choo; Felicia Fei-Lei Chung; Ling-Wei Hii; Si Hoey Tan; Nelson Tze Woei Khor; Shew Fung Wong; Sze-Jia See; Yuen-Fen Tan; Rozita Rosli; Soon-Keng Cheong; Chee-Onn Leong
Journal:  Oncotarget       Date:  2016-09-06
View more
  7 in total

1.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

2.  Glutor, a Glucose Transporter Inhibitor, Exerts Antineoplastic Action on Tumor Cells of Thymic Origin: Implication of Modulated Metabolism, Survival, Oxidative Stress, Mitochondrial Membrane Potential, pH Homeostasis, and Chemosensitivity.

Authors:  Mithlesh Kumar Temre; Saveg Yadav; Yugal Goel; Shrish Kumar Pandey; Ajay Kumar; Sukh Mahendra Singh
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

3.  Glucose Increases STAT3 Activation, Promoting Sustained XRCC1 Expression and Increasing DNA Repair.

Authors:  Griffin M Wright; Natalie R Gassman
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

Review 4.  Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.

Authors:  Doris Loh; Russel J Reiter
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

Review 5.  Metformin and Breast Cancer: Where Are We Now?

Authors:  Mónica Cejuela; Begoña Martin-Castillo; Javier A Menendez; Sonia Pernas
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 6.  Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.

Authors:  Tsvetalina Tankova; Elżbieta Senkus; Maria Beloyartseva; Simona Borštnar; Doina Catrinoiu; Mona Frolova; Alinta Hegmane; Andrej Janež; Mladen Krnić; Zoltan Lengyel; Yiola Marcou; Laura Mazilu; Bela Mrinakova; Ruth Percik; Katarina Petrakova; Gábor Rubovszky; Margarita Tokar; Eduard Vrdoljak
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

Review 7.  Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy.

Authors:  Yaseen Hussain; Haroon Khan; Waqas Alam; Michael Aschner; Khalaf F Alsharif; Luciano Saso
Journal:  Oxid Med Cell Longev       Date:  2022-06-27       Impact factor: 7.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.